$321.29 +9.88 (%) Biogen Idec Inc - NASDAQ

Oct. 21, 2014 | 12:36 PM

Partner Headlines

  1. Celgene Reports More Good Crohn's Disease Data

    IBD | Oct. 21, 2014 | 11:32AM EST
  2. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD | Oct. 20, 2014 | 11:16AM EST
  3. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD | Oct. 18, 2014 | 08:02AM EST
  4. Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals

    IBD | Oct. 16, 2014 | 15:07PM EST
  5. IPO Stock Watch: Biotech Forward Pharma Falls On IPO

    IBD | Oct. 15, 2014 | 16:06PM EST
  6. Major Averages Pare Losses, Then Head Lower Again

    IBD | Oct. 15, 2014 | 12:01PM EST
  7. IBD 50: Medical, Internet Companies Top Q3 Estimates

    IBD | Oct. 13, 2014 | 19:15PM EST
  8. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD | Oct. 13, 2014 | 16:33PM EST
  9. Which Fund Has The Most To Gain From Biogen Idec?

    Benzinga | Oct. 13, 2014 | 10:05AM EST
  10. IBD 50: Medical, Internet Companies Top Q3 Profit Estimates

    IBD | Oct. 10, 2014 | 18:45PM EST
  11. Most Top Industry Groups Fall Harder Than Market

    IBD | Oct. 10, 2014 | 17:58PM EST
  12. Biogen Idec Inc's Stock Is Set To Drop

    Benzinga | Oct. 9, 2014 | 07:26AM EST
  13. Second Oldest Stock Fund Is As Nimble As A Teenager

    IBD | Oct. 2, 2014 | 18:25PM EST
  14. Top Fund Buys: Chipotle, Allergan, Jazz, Gilead

    IBD | Oct. 2, 2014 | 18:25PM EST
  15. Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20%

    GuruFocus | Oct. 1, 2014 | 17:39PM EST
  16. Biogen Idec Inc Still Showing Relative Weakness Compared To Biotech Peers

    Benzinga | Sep. 30, 2014 | 15:17PM EST
  17. Biotech Stocks Rebound On Strong Earnings, New Drugs

    IBD | Sep. 29, 2014 | 18:32PM EST
  18. Large-Cap Tech, Biotech Names Hang Tough In Shaky Market

    IBD | Sep. 29, 2014 | 18:32PM EST
  19. New MS Drugs Offer Promise

    IBD | Sep. 26, 2014 | 18:56PM EST
  20. Multiple Sclerosis Drugs Could Transform Market Again

    IBD | Sep. 26, 2014 | 18:07PM EST
  21. Technology Stocks Slide But Other Sectors Hold Up Better

    IBD | Sep. 25, 2014 | 18:55PM EST
  22. A Few Reasons Why AbbVie's Momentum Will Continue

    GuruFocus | Sep. 25, 2014 | 17:53PM EST
  23. Stocks Get Hit Hard; GoPro, Skechers Buck Weakness

    IBD | Sep. 25, 2014 | 16:23PM EST
  24. Wave Of Selling Hits Stocks; IPO CyberArk Extends Gains

    IBD | Sep. 25, 2014 | 13:31PM EST
  25. Apple Fuels Tech Sell-Off; Valeant Bucks The Trend

    IBD | Sep. 25, 2014 | 11:34AM EST
  26. Stocks End Skid; Vertex, Alexion Lead Biotech Rebound

    IBD | Sep. 24, 2014 | 16:16PM EST
  27. Stocks Up In Afternoon; Hasbro Jumps On Disney Deal

    IBD | Sep. 24, 2014 | 15:05PM EST
  28. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD | Sep. 24, 2014 | 13:27PM EST
  29. Stocks Hold Solid Gains; CyberArk Soars In Debut

    IBD | Sep. 24, 2014 | 13:20PM EST
  30. Most Big Cap 20 Stocks Near Entries, But Risks Exist

    IBD | Sep. 22, 2014 | 19:05PM EST
  31. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD | Sep. 19, 2014 | 12:17PM EST
  32. 2 Columbia Growth Funds Notch Impressive Three-Month Performance

    Benzinga | Sep. 18, 2014 | 10:52AM EST
  33. Nasdaq Falls Hard, But Apple Resilient On iPhone Orders

    IBD | Sep. 15, 2014 | 14:55PM EST
  34. Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers

    IBD | Sep. 13, 2014 | 08:02AM EST
  35. Why Nine of Fifteen Oil Majors Are Undervalued

    YCharts | Sep. 12, 2014 | 18:34PM EST
  36. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD | Sep. 11, 2014 | 17:41PM EST
  37. Stocks Show Modest Losses; Biotechs Pressured Again

    IBD | Sep. 11, 2014 | 14:46PM EST
  38. Biogen Idec Inc Suddenly Struggling To Keep Up With The Biotech Joneses

    Benzinga | Sep. 11, 2014 | 08:17AM EST
  39. Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of Efficacy, Safety in MS Patients

    Benzinga | Sep. 11, 2014 | 07:32AM EST
  40. Biogen Announces Five-Year Results from ENDORSE Phase 3 Study Show TECFIDERA Provides Strong, Sustained Efficacy for RRMS

    Benzinga | Sep. 11, 2014 | 07:31AM EST
  41. Stocks Turn Higher After Soft Start; U.S. Silica Jumps

    IBD | Sep. 10, 2014 | 13:25PM EST
  42. ReceptosMS Drug Yields More Good Data; Stock Jumps

    IBD | Sep. 10, 2014 | 11:58AM EST
  43. Steadier, Better: 35 Years Of Low-Volatility Stocks

    YCharts | Sep. 8, 2014 | 20:54PM EST
  44. Allianz's Analyst Likes Biogen, Celgene & Gilead

    Benzinga | Sep. 6, 2014 | 17:28PM EST
  45. Indexes Trim Losses But Remain Lower At Midday

    IBD | Sep. 5, 2014 | 12:04PM EST
  46. Biogen: Moving From Collaboration To Innovation

    IBD | Aug. 29, 2014 | 16:14PM EST
  47. Economic Data Fuel Another All-Time High For S&P 500

    IBD | Aug. 26, 2014 | 15:36PM EST
  48. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD | Aug. 26, 2014 | 14:38PM EST
  49. Biogen, Celgene In Buy Range; LinkedIn Coming Back

    IBD | Aug. 25, 2014 | 18:43PM EST
  50. Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs

    IBD | Aug. 25, 2014 | 14:54PM EST
Trading Center